Journal
ACS APPLIED MATERIALS & INTERFACES
Volume 9, Issue 50, Pages 43538-43544Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsami.7b16118
Keywords
mesoporous silica; adjuvant; cancer immunotherapy; doping; Th1 immune; degradation
Funding
- JSPS KAKENHI [17K01399]
- Nippon Sheet Glass Foundation for Materials Science and Engineering
- Grants-in-Aid for Scientific Research [17K01399] Funding Source: KAKEN
Ask authors/readers for more resources
Modern vaccines usually require accompanying adjuvants to increase the immune response to antigens. Aluminum (alum) compounds are the most commonly used adjuvants in human vaccinations for infection diseases. However, alum adjuvants are nondegradable, cause side effects due to the persistence of alum at injection sites, and are rather ineffective for cancer immunotherapy, which requires the Th1 immune response. Recently, we have shown that a plain mesoporous silica (MS) adjuvant can stimulate Th1 anticancer immunity for cancer vaccines. Herein, MS nanospheres doped with Ca, Mg, and Zn (MS-Ca, MS-Mg, and MS-Zn) showed significantly higher degradation rates than pure MS. Moreover, MS-Ca, MS-Mg, and MS-Zn nanospheres stimulated anticancer immune response and increased the CD4(+) and CD8(+) T cell populations in spleen. The MS-Ca, MS-Mg, and MS-Zn nanospheres with improved biodegradability and excellent ability to induce Th1 anticancer immunity show potential for clinical applications as cancer immunoadjuvants.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available